Congress juggles two crucial drug bills

With the Senate poised to vote tomorrow on PDUFA, the House is taking up consideration of legislation that would create a regulatory pathway for generic biotech drugs, or follow-on therapies. Rep. Henry Waxman introduced the biogeneric bill last February. Advocates say that the best shot to gain passage of the bill would come if it is folded into PDUFA reauthorization, which would enable the FDA to gather fees from drug developers for another five years. So far, however, that hasn't happened, which could endanger any follow-on legislation from gaining acceptance. The Senate dropped a move to add the generic legislation to the PDUFA bill and lawmakers say they will take up the issue separately. One of the first biotech companies to face generic competition, if it is approved, is Amgen, which makes Epogen and Neupogen.

- read the report from CNN
- and here's the article on PDUFA from The New York Times

Suggested Articles

Biogen unveiled full phase 1/2 for a prospect that emerged from a shift in its thinking about treating amyotrophic lateral sclerosis.

It took a little longer than expected, but Biogen’s done it—along with partner Eisai, the Big Biotech has completed an FDA filing for aducanumab.

Gilead is ditching a new avenue of treating hepatitis B as it cuts ties with Precision Biosciences less than two years into their research pact.